T
Tomomi Kaneko
Researcher at GlaxoSmithKline
Publications - 4
Citations - 592
Tomomi Kaneko is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Lapatinib & Capecitabine. The author has an hindex of 4, co-authored 4 publications receiving 494 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
J. Randolph Hecht,Yung-Jue Bang,Shukui K. Qin,Hyun Cheol Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Zev A. Wainberg,Marc Buyse,Karen Afenjar,Vincent Houe,Agathe Garcia,Tomomi Kaneko,Yingjie Huang,Saba Khan-Wasti,Sergio Santillana,Michael F. Press,Dennis J. Slamon +23 more
TL;DR: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma, and no correlation was observed between HER2 immunohistochemistry status and survival.
Journal ArticleDOI
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
J. Randolph Hecht,Yung-Jue Bang,Shukui Qin,Hyun Chul Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Marc Buyse,Karen Afenjar,Tomomi Kaneko,Allison Kemner,Sergio Santillana,Michael F. Press,Dennis J. Slamon +19 more
TL;DR: The addition of L to CapeOx did not reach its primary endpoint, though certain subgroups showed improvement, and the analysis of PFS censored by the time of subsequent anticancer therapy as per protocol showed a significant improvement.
Journal ArticleDOI
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.
J. Randolph Hecht,Yung-Jue Bang,Shukui Qin,Hyun Chul Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana Protsenko,Marc Buyse,Karen Afenjar,Tomomi Kaneko,Allison Kemner,Sergio Santillana,Michael F. Press,Dennis J. Slamon +19 more
TL;DR: This abstract describes a simple, scalable, scalable and scalable approaches that can be applied to the rapidly changing environment and provide real-time information about the response of the immune system to central nervous system injuries.
Journal ArticleDOI
Brain and tumor penetration of carbon-11–labeled lapatinib ([11C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).
Azeem Saleem,Graham E. Searle,Laura M. Kenny,Mickael Huiban,Adam D. Waldman,Louise Downie,M. Lau,Philip S Murphy,Kasia Kozlowski,Yvonne Lewis,Laura Woodley,Sam Hill,Aruloly Kamalakaran,Sandra Hirschberg,Tomomi Kaneko,Eric O. Aboagye,Luca Marini,R. Charles Coombes +17 more
TL;DR: A small number of patients diagnosed with HER2-overexpressing breast cancer will develop brain metastases in the course of their disease and drug access to normal brain and brain metastase treatment is restricted.